<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
  <meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
  <meta http-equiv="Content-Style-Type" content="text/css" />
  <meta name="generator" content="pandoc" />
  <title></title>
  <style type="text/css">code{white-space: pre;}</style>
</head>
<body>
<h3 id="mondo0015901"><a href="http://purl.obolibrary.org/obo/MONDO_0015901">MONDO:0015901</a></h3>
<p><strong>Label:</strong> rare hyperlipidemia</p>
<p><strong>Subclasses:</strong> <a href="http://purl.obolibrary.org/obo/MONDO_0018328">MONDO:0018328</a> (homozygous familial hypercholesterolemia), <a href="http://purl.obolibrary.org/obo/MONDO_0007744">MONDO:0007744</a> (cholesterol-ester transfer protein deficiency), <a href="http://purl.obolibrary.org/obo/MONDO_0018799">MONDO:0018799</a> (rare hypercholesterolemia), <a href="http://purl.obolibrary.org/obo/MONDO_0019247">MONDO:0019247</a> (combined hyperlipidemia), <a href="http://purl.obolibrary.org/obo/MONDO_0015903">MONDO:0015903</a> (hyperalphalipoproteinemia), <a href="http://purl.obolibrary.org/obo/MONDO_0015902">MONDO:0015902</a> (major hypertriglyceridemia), <a href="http://purl.obolibrary.org/obo/MONDO_0018637">MONDO:0018637</a> (familial chylomicronemia syndrome),</p>
<p><strong>Corr. equiv. classes:</strong> <a href="http://www.orpha.net/ORDO/Orphanet_477811">Orphanet:477811</a>, <a href="http://www.orpha.net/ORDO/Orphanet_181428">Orphanet:181428</a>, <a href="http://www.orpha.net/ORDO/Orphanet_391665">Orphanet:391665</a>, <a href="http://www.orpha.net/ORDO/Orphanet_181425">Orphanet:181425</a>, <a href="http://www.orpha.net/ORDO/Orphanet_79506">Orphanet:79506</a>, <a href="http://purl.obolibrary.org/obo/OMIM_602247">OMIM:602247</a>, <a href="http://www.orpha.net/ORDO/Orphanet_444490">Orphanet:444490</a>, <a href="http://purl.obolibrary.org/obo/OMIM_118830">OMIM:118830</a>, <a href="http://purl.obolibrary.org/obo/OMIM_603813">OMIM:603813</a>, <a href="http://purl.obolibrary.org/obo/OMIM_143890">OMIM:143890</a>, <a href="http://purl.obolibrary.org/obo/OMIM_207750">OMIM:207750</a>, <a href="http://purl.obolibrary.org/obo/OMIM_143470">OMIM:143470</a>, <a href="http://purl.obolibrary.org/obo/OMIM_614028">OMIM:614028</a>, <a href="http://purl.obolibrary.org/obo/OMIM_615947">OMIM:615947</a>, <a href="http://purl.obolibrary.org/obo/OMIM_238600">OMIM:238600</a>, <a href="http://www.orpha.net/ORDO/Orphanet_79211">Orphanet:79211</a>,</p>
<p><strong>Class expressions from DL-Learner:</strong></p>
<ul>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0003141">HP:0003141</a> (Increased circulating low-density lipoprotein levels))) 71.88%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0010981">HP:0010981</a> (Hypolipoproteinemia))) 69.72%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0003233">HP:0003233</a> (Decreased circulating high-density lipoprotein levels))) 69.72%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0012823">HP:0012823</a> (Clinical modifier))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0012144">HP:0012144</a> (Abnormality of cells of the monocyte/macrophage lineage))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0011492">HP:0011492</a> (Abnormality of corneal stroma))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0010987">HP:0010987</a> (Abnormality of cellular immune system))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0010974">HP:0010974</a> (Abnormality of myeloid leukocytes))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0010876">HP:0010876</a> (Abnormality of circulating protein level))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0007957">HP:0007957</a> (Corneal opacity))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0007759">HP:0007759</a> (Opacification of the corneal stroma))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0005561">HP:0005561</a> (Abnormality of bone marrow cell morphology))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0004328">HP:0004328</a> (Abnormality of the anterior segment of the globe))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0004311">HP:0004311</a> (Abnormality of macrophages))) 67.64%</li>
<li><a href="http://purl.obolibrary.org/obo/HP_0010980">HP:0010980</a> (Hyperlipoproteinemia) and (not (<a href="http://purl.obolibrary.org/obo/HP_0003011">HP:0003011</a> (Abnormality of the musculature))) 67.64%</li>
</ul>
</body>
</html>
